Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site
about
Antigen-specific immunotherapy of cervical and ovarian cancerPerspectives for therapeutic HPV vaccine developmentPerspectives for preventive and therapeutic HPV vaccines.Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunityImmunotherapy for cervical cancer: Research status and clinical potentialAdjuvant properties of listeriolysin O protein in a DNA vaccination strategy.Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculatureToll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγThe timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cellsAdenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse modelsWhole tumor antigen vaccines.A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.Against the self: dendritic cells versus cancer.Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.Lm-LLO-Based Immunotherapies and HPV-Associated DiseaseRecent developments in human papillomavirus vaccines.Vaccination strategies for the prevention of cervical cancer.Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic abilityEffects of the tumor microenvironment on the efficacy of tumor immunotherapy.Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.Human papillomavirus vaccines for the treatment of cervical cancer.Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.Human papillomavirus therapeutic vaccines in head and neck tumors.A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia.Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.Cancer immunotherapy using Listeria monocytogenes and listerial virulence factorsListeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines.Live-attenuated Listeria-based immunotherapy.Current state in the development of candidate therapeutic HPV vaccinesThe current state of therapeutic and T cell-based vaccines against human papillomaviruses.Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers.Therapeutic human papillomavirus vaccines: current clinical trials and future directionsEmerging human papillomavirus vaccinesThe Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
P2860
Q27488697-F37BDD69-D5C2-426E-B244-EEBF9CF3D8ABQ28069272-663A30C7-C3D8-456C-B307-A62BC94408D7Q34011494-0ADE2599-A90E-4F16-8F48-49E54BA8B737Q34033407-8E078920-764A-4607-8506-B1511FFA61E9Q34033763-34613B68-8839-4B1F-9C4C-4B7420FAB44AQ34267760-FC80C7B2-320B-46E6-BED7-CAA62957AF68Q34415243-502CCC53-82C3-4A46-AC00-1062A67F60DAQ34438411-3ACFE992-0AEC-4C54-9197-451120A3191DQ34832951-B8D23B36-F541-435E-AC51-057D8F389742Q34988018-92FDEE72-D2CA-4917-A3D7-1855489DB486Q35058235-277A91FA-C080-47B5-AEC2-1E677320686EQ35154570-AA4CFF1C-DA77-427B-897A-523898886F08Q35219334-986CB8D0-46AB-4FB9-86EC-8D242682EE75Q35552591-42CE5DD2-0CAC-45B2-AB11-F9A7A844723DQ35771342-CB299185-EB4C-4A72-A35C-1C2BAC28C330Q35838127-46E39200-D756-4BFB-AD7F-3579195A5D27Q35842528-D49B2243-E469-4F32-A4BC-AA80479C0589Q36066161-26518CE1-A012-47F4-BA46-45B8FD4E5B5BQ36504822-554B3E2C-B401-4920-94F2-93817ED066C3Q36569004-055737A7-3ACA-47C5-A710-96D21000A03FQ36672543-2B2C2C96-F791-4266-9454-20F24C4D5AAAQ36690278-6266D707-E355-4790-A3BB-023957121F92Q36691357-C67D4249-2FC4-4EDB-8D83-BF6CF911E2F0Q36757129-32CE1E31-231C-44EA-8481-EF6DD5B68A14Q36817148-EC5E9B4F-18B6-46C5-A62D-E6949E1D6833Q37151172-8F0D1DF8-6F5A-4799-8423-94744B158067Q37374278-9E5AA1EA-5086-4209-BCB9-FEA406303D6BQ37391236-54415224-22BC-4698-A3BC-30B881479014Q37582872-D9CFF959-D470-44D6-9CCA-A76578DFC863Q38105337-979DB31D-6351-4923-9033-99BA0F232C48Q38743922-C0B12CDF-EEF1-4E2C-9960-21706C1567F4Q39033576-81DA9FF7-E55D-43A6-8E2C-EE313C26C4BCQ39235934-BAA5ACBD-4179-4F99-818D-D82A5EE9DC92Q39796159-73105DF3-5CB0-41A8-B189-CDFD5B441E89Q43854654-69D4082B-C9A1-4D9E-B71C-66C71BBEDE2BQ45888118-5EFE5AC3-A7BB-4503-A907-C61F8C458FD3Q56937332-4C16C24D-7F4E-4F7B-88F6-F41E0C7F5F45Q56967486-2633D208-AE60-4DE5-8AC0-D03264D73A87Q58750585-DFF46082-911D-4697-A52D-4619BD32F7DE
P2860
Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Regression of established huma ...... es that home to the tumor site
@ast
Regression of established huma ...... es that home to the tumor site
@en
type
label
Regression of established huma ...... es that home to the tumor site
@ast
Regression of established huma ...... es that home to the tumor site
@en
prefLabel
Regression of established huma ...... es that home to the tumor site
@ast
Regression of established huma ...... es that home to the tumor site
@en
P2093
P2860
P1433
P1476
Regression of established huma ...... es that home to the tumor site
@en
P2093
P2860
P304
P356
10.1128/JVI.75.20.9654-9664.2001
P577
2001-10-01T00:00:00Z